SIBN logo

SI-BONE INC

SIBNNASDAQ
πŸ† #2394 by market capEarnings Nov 2 Β· PostUS Equity
$22.41β–² $0.58 (+2.66%)
πŸŒ™ After hours$22.40β–Ό 0.04%Regular close Β· extended-hours price shown
πŸ””
Track SIBN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.7%
7dβ–² 4.4%
14dβ–² 13.9%
30dβ–² 19.1%
ytdβ–² 13.6%
1yβ–² 47.8%
🏦Market Cap
$1.00B
Small Cap
πŸ“ˆRevenue Growth (YoY)
20.2%
Healthy
πŸ“ŠGross Margin
79.5%
High
πŸ’΅FCF Margin
-2.0%
Thin
βš–οΈP/S Ratio
4.6x
Fair
Otter Score
72
Strong

Trading Snapshot

Day Range
$21.83 – $22.94
52-Week Range
$11.48 – $21.96
Volume (shares)
950,281
Avg Volume (shares)
β€”
Shares Outstanding
44.8M
Next Earnings
2026-11-02

Fundamentals Snapshot

Annual Revenue
$201M
Last Q Revenue
$56M
P/E Ratio
-64.2
P/S Ratio
4.6x
EPS (TTM)
$-0.33
Dividend Yield
0.00%
Dilution (1yr)
+3.6%
SIBN logo

SI-BONE INC

SIBN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$201Mβ–² +20.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.6%β–² +0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$22Mβ–Ό βˆ’36.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$9Mβ–Ό βˆ’60.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
43.5Mβ–² +3.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$41Mβ–² +$44M YoY
StockOtter Β· stockotter.space

About SI-BONE INC

SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·10h ago

SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026

SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that

GlobeNewsWireΒ·10d ago

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026

SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it wil

GuruFocusΒ·17d ago

Is SI-BONE Inc (SIBN) Overvalued After 3.8% Rally? GF Value Says Overvalued

On October 12, 2026, SI-BONE Inc (SIBN) shares rose 3.8% to a current price of $20.10. This movement comes amid a 52-week range that saw a high of $21.89 and a

Defense WorldΒ·24d ago

Analyzing SiBone (NASDAQ:SIBN) & Integer (NYSE:ITGR)

Integer (NYSE: ITGR - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuati

GlobeNewsWireΒ·Sep 28

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyxβ„’, Extending Its Compromised Bone Franchise Beyond the Pelvis

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

Seeking AlphaΒ·Sep 14

SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript